Roubaix Capital LLC bought a new position in shares of BioSpecifics Technologies Corp. (NASDAQ:BSTC) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 45,142 shares of the biopharmaceutical company’s stock, valued at approximately $2,695,000. BioSpecifics Technologies makes up approximately 2.2% of Roubaix Capital LLC’s investment portfolio, making the stock its 23rd biggest position. Roubaix Capital LLC owned 0.62% of BioSpecifics Technologies as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Advantage Investment Management LLC increased its position in BioSpecifics Technologies by 40.9% during the 2nd quarter. Advantage Investment Management LLC now owns 957 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 278 shares in the last quarter. Eagle Asset Management Inc. grew its position in BioSpecifics Technologies by 0.5% in the first quarter. Eagle Asset Management Inc. now owns 66,097 shares of the biopharmaceutical company’s stock valued at $4,119,000 after acquiring an additional 329 shares in the last quarter. Legal & General Group Plc grew its position in BioSpecifics Technologies by 50.1% in the fourth quarter. Legal & General Group Plc now owns 1,211 shares of the biopharmaceutical company’s stock valued at $74,000 after acquiring an additional 404 shares in the last quarter. Navellier & Associates Inc grew its position in BioSpecifics Technologies by 3.5% in the second quarter. Navellier & Associates Inc now owns 16,309 shares of the biopharmaceutical company’s stock valued at $974,000 after acquiring an additional 554 shares in the last quarter. Finally, Globeflex Capital L P grew its position in BioSpecifics Technologies by 17.3% in the first quarter. Globeflex Capital L P now owns 6,802 shares of the biopharmaceutical company’s stock valued at $424,000 after acquiring an additional 1,002 shares in the last quarter. 58.19% of the stock is owned by hedge funds and other institutional investors.
In related news, Director Paul Gitman sold 5,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $65.83, for a total transaction of $329,150.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jennifer M. Chao sold 4,000 shares of the firm’s stock in a transaction on Friday, May 17th. The stock was sold at an average price of $63.72, for a total value of $254,880.00. Following the transaction, the director now owns 3,313 shares in the company, valued at $211,104.36. The disclosure for this sale can be found here. Insiders have sold 37,583 shares of company stock worth $2,309,328 over the last 90 days. 16.39% of the stock is currently owned by company insiders.
Shares of BioSpecifics Technologies stock traded down $1.69 on Friday, hitting $56.55. 51,655 shares of the company’s stock traded hands, compared to its average volume of 57,975. The firm has a market capitalization of $408.80 million, a PE ratio of 20.71 and a beta of 1.21. The business’s 50-day simple moving average is $59.79. BioSpecifics Technologies Corp. has a 52-week low of $45.55 and a 52-week high of $73.31.
BioSpecifics Technologies (NASDAQ:BSTC) last announced its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.62 by ($0.02). BioSpecifics Technologies had a return on equity of 21.08% and a net margin of 59.99%. The firm had revenue of $8.13 million for the quarter, compared to the consensus estimate of $8.10 million. As a group, sell-side analysts predict that BioSpecifics Technologies Corp. will post 3 EPS for the current year.
About BioSpecifics Technologies
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands.
Read More: Cash Flow Analysis in Stock Selection
Want to see what other hedge funds are holding BSTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioSpecifics Technologies Corp. (NASDAQ:BSTC).
Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.